Characterization of Single Dose Bioavailability of Two Novel Formulations of BAY 2328065 in Healthy Male Participants Including Dose Proportionality of One Formulation and Investigation of Safety, Tolerability and Pharmacokinetics of Multiple Dose Administration in Healthy Female Participants
Latest Information Update: 03 Jun 2022
At a glance
- Drugs BAY-2328065 (Primary)
- Indications Endometriosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 12 Apr 2022 Status changed from active, no longer recruiting to completed.
- 28 Dec 2021 Planned End Date changed from 26 Jan 2022 to 2 Feb 2022.
- 06 Dec 2021 Planned End Date changed from 10 Jan 2022 to 26 Jan 2022.